Surrozen, Inc./DE Operating Cash Flow
Surrozen, Inc./DE (SRZN) reported Operating Cash Flow of -$19.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Surrozen, Inc./DE net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$7.42M.
- Surrozen, Inc./DE net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.49M.
- Surrozen, Inc./DE net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.81M, a 266.96% decline year-over-year.
- Surrozen, Inc./DE net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.04M.
- Surrozen, Inc./DE net cash provided by (used in) operating activities for fiscal 2025 was -$30.24M.
- Surrozen, Inc./DE net cash provided by (used in) operating activities for fiscal 2024 was -$17.63M.
- Surrozen, Inc./DE net cash provided by (used in) operating activities for fiscal 2023 was -$40.36M.
- Surrozen, Inc./DE net cash provided by (used in) operating activities for fiscal 2022 was -$44.15M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 4 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$7.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$19.91M 10-Q · filed 2026-08-06 | -$25.72M derived: sum of 3 quarters · filed 2026-08-06 | -$34.76M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$12.49M 10-Q · filed 2026-05-06 | -$18.31M derived: sum of 2 quarters · filed 2026-05-06 | -$27.35M derived: sum of 3 quarters · filed 2026-05-06 | -$33.46M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$5.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$14.85M derived: sum of 2 quarters · filed 2026-03-23 | -$20.96M derived: sum of 3 quarters · filed 2026-08-06 | -$30.24M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | -$9.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$15.15M derived: sum of 2 quarters · filed 2026-08-06 | -$24.43M 10-Q · filed 2025-11-07 | -$20.95M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$6.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$15.39M 10-Q · filed 2026-08-06 | -$11.91M derived: sum of 3 quarters · filed 2026-08-06 | -$18.66M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$9.28M 10-Q · filed 2026-05-06 | -$5.80M derived: sum of 2 quarters · filed 2026-05-06 | -$12.55M derived: sum of 3 quarters · filed 2026-05-06 | -$18.16M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$3.27M derived: sum of 2 quarters · filed 2026-03-23 | -$8.88M derived: sum of 3 quarters · filed 2026-03-23 | -$17.63M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | -$6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$12.36M derived: sum of 2 quarters · filed 2025-11-07 | -$21.11M 10-Q · filed 2025-11-07 | -$28.42M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | -$5.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$14.36M 10-Q · filed 2025-08-08 | -$21.67M derived: sum of 3 quarters · filed 2025-08-08 | -$31.80M derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-03-31 | -$8.75M 10-Q · filed 2025-05-09 | -$16.06M derived: sum of 2 quarters · filed 2025-05-09 | -$26.19M derived: sum of 3 quarters · filed 2025-05-09 | -$34.94M derived: sum of 4 quarters · filed 2025-05-09 | |||
| 2023-12-31 | -$7.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$17.44M derived: sum of 2 quarters · filed 2025-03-31 | -$26.19M derived: sum of 3 quarters · filed 2025-03-31 | -$40.36M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$10.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$18.88M derived: sum of 2 quarters · filed 2024-11-06 | -$33.05M 10-Q · filed 2024-11-06 | -$33.26M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$8.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$22.92M 10-Q · filed 2024-08-12 | -$23.12M derived: sum of 3 quarters · filed 2024-08-12 | -$37.28M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | -$14.17M 10-Q · filed 2024-05-08 | -$14.38M derived: sum of 2 quarters · filed 2024-05-08 | -$28.53M derived: sum of 3 quarters · filed 2024-05-08 | -$39.94M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | -$205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -$14.36M derived: sum of 2 quarters · filed 2024-04-10 | -$25.77M derived: sum of 3 quarters · filed 2024-04-10 | -$44.15M 10-K · filed 2024-04-10 | |||
| 2022-09-30 | -$14.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$25.57M derived: sum of 2 quarters · filed 2023-11-08 | -$43.94M 10-Q · filed 2023-11-08 | -$55.48M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | -$11.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$29.79M 10-Q · filed 2023-08-09 | -$41.33M derived: sum of 3 quarters · filed 2023-08-09 | -$55.39M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | -$18.37M 10-Q · filed 2023-05-10 | -$29.92M derived: sum of 2 quarters · filed 2023-05-10 | -$43.98M derived: sum of 3 quarters · filed 2023-05-10 | -$56.85M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | -$11.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$25.60M derived: sum of 2 quarters · filed 2023-03-31 | -$38.48M derived: sum of 3 quarters · filed 2023-03-31 | -$48.81M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$14.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$26.94M derived: sum of 2 quarters · filed 2022-11-14 | -$37.27M 10-Q · filed 2022-11-14 | -$46.61M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$12.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$23.21M 10-Q · filed 2022-08-11 | -$596.51K 10-Q · filed 2021-08-09 | -$32.55M derived: sum of 3 quarters · filed 2022-08-11 | |||
| 2021-03-31 | -$10.33M 10-Q · filed 2022-05-11 | -$212.26K 10-Q · filed 2021-05-24 | -$19.67M derived: sum of 2 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | -$9.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$933.99K 10-K/A · filed 2021-05-14 | -$29.10M 10-K · filed 2022-03-28 | ||||
| 2020-09-30 | -$19.76M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |